Sotrovimab, ib qho tshuaj tiv thaiv kab mob monoclonal twb tau pom zoo rau me me mus rau nruab nrab COVID-19 hauv ntau lub tebchaws tau txais kev pom zoo los ntawm MHRA hauv UK. Cov tshuaj tiv thaiv kab mob no tau ntse tsim nrog tus kab mob hloov pauv hauv siab. Ib cheeb tsam uas tau txais kev cawmdim heev ntawm cov kab mob loj heev tau tsom mus rau qhov tsis tshua muaj kev hloov pauv, nrog rau kev cia siab los daws ob qho tib si yav dhau los thiab tam sim no. txawv of SARS-CoV-2 virus (Omicron) and the future txawv, uas yuav inevitable.
Xeduvy (sotrovimab), a monoclonal tshuaj tiv thaiv ua los ntawm kev sib koom tes ntawm GSK thiab Vir Biotechnology uas twb tau pom zoo rau cov neeg mob me me mus rau nruab nrab COVID-19 hauv ntau lub tebchaws (Australia, Canada, Tebchaws USA), tsis ntev los no tau tso cai ua lag luam los ntawm MHRA, UK1 siv rau cov neeg mob COVID-19 hauv 5 hnub txij li pib kis tus kab mob. Nws tau pom tias muaj kev nyab xeeb thiab siv tau zoo thiab txo qhov kev pheej hmoo ntawm kev mus pw hauv tsev kho mob los ntawm 79%. Cov yam ntxwv tseem ceeb ntawm sotrovimab yog tias nws tau tsom mus rau thaj tsam uas tau txais txiaj ntsig zoo ntawm cov protein ntau ntawm SARS-CoV-2, uas tsis tshua muaj kev hloov pauv. Lub cheeb tsam no ntawm SARS-CoV-2 yog sib koom nrog SARS-CoV-1 (tus kab mob uas ua rau SARS)2, qhia tau hais tias thaj av ntawd tau txais kev cawmdim heev, yog li ua rau nws nyuaj rau kev tiv thaiv kev txhim kho. Qhov no feature ua sotrovimab ua hauj lwm tawm tsam tag nrho cov txawv ntawm COVID-19 muaj nyob rau tam sim no, suav nrog omicron. Nws kuj tseem yuav ua haujlwm rau yav tom ntej txawv ib yam nkaus, tsuav yog qhov kev hloov pauv tsis tshwm sim hauv thaj chaw khaws cia3 ntawm spike protein ntawm SARS-CoV-2, uas tsis tau pom txog tam sim no.
Sotrovimab tuaj yeem ua raws li cov mos txwv khawv koob tiv thaiv txhua tus paub thiab tsis paub yav tom ntej txawv (uas yog qhov kev zam tsis tau vim tus kab mob sib sau ntau qhov kev hloov pauv los ntawm kev sib kis ntau dua) ntawm COVID-19. Lub hauv paus ntsiab lus ntawm kev txhim kho sotrovimab los ntawm kev tsom mus rau thaj chaw khaws cia ntawm cov protein ntau, tuaj yeem siv rau kev txhim kho ntxiv ntawm cov tshuaj tiv thaiv kab mob monoclonal thiab tshuaj tiv thaiv tiv thaiv COVID-19.
***
References:
- GSK 2021. Xov xwm tshaj tawm - MHRA muab kev tso cai ua lag luam raws cai1 rau kev kho mob COVID-19 Xevudy (sotrovimab). Published 02 December 2021. Muaj nyob ntawm https://www.gsk.com/en-gb/media/press-releases/mhra-grants-conditional-marketingauthorisation1-for-covid-19-treatment-xevudy-sotrovimab/
- GSK 2021. Xovxwm tshaj tawm – Cov ntaub ntawv ua ntej qhia pom tias sotrovimab khaws cov haujlwm tiv thaiv qhov tseem ceeb Omicron mutations, SARS-CoV-2 variant tshiab. Published 02 December 2021. Muaj nyob ntawm https://www.gsk.com/en-gb/media/press-releases/preclinical-data-demonstratesotrovimab-retains-activity-against-key-omicron-mutations-new-sars-cov-2-variant/
- Pinto, D., Park, YJ., Beltramello, M. et al. Cross-neutralization of SARS-CoV-2 by human monoclonal SARS-CoV antibody. xwm 583, 290-295 (2020). https://doi.org/10.1038/s41586-020-2349-y
***
 and the future variants, that would be inevitable.){kind=link}